Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension
- PMID: 12773327
- DOI: 10.1164/rccm.200210-1212OC
Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension
Abstract
Pulmonary hypertension (PH) results from constriction and remodeling of pulmonary vessels. Serotonin contributes to both phenomena through different signaling pathways. The mitogenic effect of serotonin on pulmonary vascular smooth muscle cells is mediated by the serotonin transporter (5-hydroxytryptamine transporter [5-HTT]), whereas its constricting effect is mediated by 5-HT1B/1D and 5-HT2A receptors. Here, we investigated the respective roles of 5-HTT and 5-HT receptors on the development of chronic hypoxic PH in mice. During exposure to hypoxia (10% O2 for 2 weeks), the animals received one of the specific 5-HTT inhibitors citalopram and fluoxetine (10 mg/kg/day), the selective 5-HT1B/1D receptor antagonist GR127935 (2 and 10 mg/kg/day), or the 5-HT2A receptor antagonist ketanserin (2 mg/kg/day). Mice treated with the 5-HTT inhibitors showed less right ventricle hypertrophy (ratio of right ventricle/left ventricle + septum = 36.7 +/- 2.0% and 35.8 +/- 1.3% in citalopram- and fluoxetine-treated mice, respectively, vs. 41.5 +/- 1.5% in vehicle-treated mice) and less pulmonary vessel muscularization (p < 0.01) than those receiving the vehicle. Neither GR127935 nor ketanserin affected these parameters. These data indicate that 5-HTT plays a key role in hypoxia-induced pulmonary vascular remodeling. The effects of serotonin transporter inhibitors on PH in humans deserve investigation.
Similar articles
-
Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin.Circ Res. 1999 Feb 19;84(3):329-36. doi: 10.1161/01.res.84.3.329. Circ Res. 1999. PMID: 10024307
-
Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension.Circ Res. 2004 May 14;94(9):1263-70. doi: 10.1161/01.RES.0000126847.27660.69. Epub 2004 Apr 1. Circ Res. 2004. PMID: 15059929
-
Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene.J Clin Invest. 2000 Jun;105(11):1555-62. doi: 10.1172/JCI8678. J Clin Invest. 2000. PMID: 10841514 Free PMC article.
-
Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension?J Lab Clin Med. 2002 Apr;139(4):194-201. doi: 10.1067/mlc.2002.122181. J Lab Clin Med. 2002. PMID: 12024106 Review.
-
[The research progress on 5-hydroxytryptamine transporter].Sheng Li Ke Xue Jin Zhan. 1997 Oct;28(4):345-8. Sheng Li Ke Xue Jin Zhan. 1997. PMID: 11038689 Review. Chinese. No abstract available.
Cited by
-
Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension.Chest. 2013 Aug;144(2):531-541. doi: 10.1378/chest.12-2081. Chest. 2013. PMID: 23558791 Free PMC article.
-
miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling.Am J Physiol Lung Cell Mol Physiol. 2012 Mar 15;302(6):L521-9. doi: 10.1152/ajplung.00316.2011. Epub 2012 Jan 6. Am J Physiol Lung Cell Mol Physiol. 2012. PMID: 22227207 Free PMC article.
-
The Role of G Protein-Coupled Receptors in the Right Ventricle in Pulmonary Hypertension.Front Cardiovasc Med. 2018 Dec 17;5:179. doi: 10.3389/fcvm.2018.00179. eCollection 2018. Front Cardiovasc Med. 2018. PMID: 30619886 Free PMC article. Review.
-
Drug treatment of pulmonary arterial hypertension: current and future agents.Drugs. 2005;65(10):1337-54. doi: 10.2165/00003495-200565100-00003. Drugs. 2005. PMID: 15977967 Review.
-
Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus.Am J Physiol Lung Cell Mol Physiol. 2011 Dec;301(6):L937-44. doi: 10.1152/ajplung.00198.2011. Epub 2011 Sep 9. Am J Physiol Lung Cell Mol Physiol. 2011. PMID: 21908589 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical